The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Screening for Compounds Lowering Alpha-synuclein Expression Using a Novel Cell Line Assay
Study Rationale:
Multiple lines of evidence suggest that alpha-synuclein gain-of-function is characteristic of Parkinson’s disease (PD). Reduction of alpha-synuclein... -
Therapeutic Pipeline Program, 2015Assay-PoC for the Reduction of Endogenous Alpha-synuclein Levels in iPS-PD Neurons
Study Rationale:
Accumulation of the alpha-synuclein protein in the brain of individuals with Parkinson’s disease (PD) is a hallmark of the disease, and mutations in the... -
Therapeutic Pipeline Program, 2015Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Study Rationale:
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure... -
Therapeutic Pipeline Program, 2015Pharmacokinetics and CNS Distribution of IgG Antibodies: Quantitative Comparison of Blood-brain, Blood-CSF and CSF-brain Relationships After Intranasal and Intravascular Dosing
Study Rationale:
Immunotherapy using antibodies (large proteins) directed against alpha-synuclein is a promising, potentially disease-modifying treatment approach for... -
Research Grant, 2015Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program
Promising Outcomes of Original Grant:
Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify... -
Therapeutic Pipeline Program, 2015The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease
Study Rationale:
Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.